PharmaShots | Incisive News in 3 Shots

Subscribe Now

Larimar Therapeutics

Larimar Therapeutics Doses First Patient with Nomlabofusp in the Open Label Extension Trial for Treating Friedreich’s Ataxia

Larimar Therapeutics Doses First Patient with Nomlabofusp in the Open Label Extension Trial for Treating Friedreich’s Ataxia

March 12, 2024

Larimar Therapeutics Reports the Results for Nomlabofusp in P-II Trial for the Treatment of Friedreich’s Ataxia

Larimar Therapeutics Reports the Results for Nomlabofusp in P-II Trial for the Treatment of Friedreich’s Ataxia

February 13, 2024

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us